Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen IncfiledCriticalSugen Inc
Publication of ECSP034734ApublicationCriticalpatent/ECSP034734A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se relaciona con compuestos de indolinona sustituidos con 2-pirrol y sus sales aceptables para el uso farmacéutico que modulan la actividad de protein quinasas y así, se espera que sean útiles en a prevención y el tratamiento de afecciones celulares relacionadas tales como el cáncer.The present invention relates to indolinone compounds substituted with 2-pyrrole and its salts acceptable for pharmaceutical use that modulate protein kinase activity and thus, are expected to be useful in the prevention and treatment of related cellular conditions such as Cancer.
ECSP0347342001-02-152003-08-15
DERIVATIVES OF 3- (4-AMIDOPIRROL-2-ILMETILIDENE) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE
ECSP034734A
(en)
Compounds derived from pyrazolic heterobicycles, inhibitors of thyroxine kinase protein activity; pharmaceutical composition comprising said compounds; and use of the compounds in the treatment of a hyperproliferative disease.
Compounds derived from pyrimidin-2-yl-1h-indole, atr protein kinase inhibitors; pharmaceutical composition comprising one of the compounds; and use of the compounds in the preparation of useful medicines for the treatment of cancer.
Pharmaceutical dosage form for immediate release of the active substance 3-z- [1- (4- (n - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -n-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl-2-indolinone-monoethanesulfonate; and its use for the treatment and / or prevention of oncological and immunological diseases, among others.